Phase II Study of Pembrolizumab in Combination with Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma
This study is for women with advanced or recurrent endometrial cancer using Pembrolizumab in combination with Carboplatin and Paclitaxel chemotherapy.
This phase II trial will study the effects of pembrolizumab in combination with carboplatin/paclitaxel for the treatment of subjects with advanced or recurrent endometrial cancer.
Participants will not be paid for their participation.
- IRB Number: 1711046947 (BTCRC-GYN15-013)
- Research Study Identifier: TX8472
- Principal Investigator: Jeanne Schilder, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required